2-vinylbenzoxazole | 63359-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-vinylbenzoxazole
• 英文别名: 2-vinylbenzo[d]oxazole；2-Ethenyl-1,3-benzoxazole
• CAS: 63359-54-6
• 化学式: C₉H₇NO
• 分子量: 145.161
• InChiKey: FDRCIXUKBBBOPH-UHFFFAOYSA-N

物化性质

• 熔点：
  -16 °C
• 沸点：
  60-61 °C(Press: 1 Torr)
• 密度：
  1.116 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-vinylbenzoxazole 在 盐酸 、 sodium nitrite 作用下， 以 苯 为溶剂， 生成 1-benzooxazol-2-yl-2-nitro-ethanone
  参考文献：
  名称：

  Demina,L.A. et al., Journal of Organic Chemistry USSR (English Translation), 1979, vol. 15, p. 654 - 659

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基苯并唑 在 sodium hydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 2.92h， 生成 2-vinylbenzoxazole
  参考文献：
  名称：

  Copper(I) salt-mediated arylation of phosphinyl-stabilized carbanions and synthetic application to heterocyclic compounds

  摘要：

  The copper-mediated reaction of phosphinyl-stabilized carbanions 2a-c with aryl halides 1a-i in DMF or HMPA produced (arylmethyl)phosphonates 3-11 in good yields. Similar treatment of N-(2-iodophenyl)- and N-(2-iodophenyl)-N-methyl-alpha-(diethoxyphosphinyl)acetamides (12 and 14) led to 2-[(diethoxyphosphinyl)methyl]benzoxazole (13) and 1-methyl-3-(diethoxyphosphinyl)oxindole (15) in 71 and 85% yields, respectively. 4-(Ethoxycarbonyl)-3,4-dihydroisoquinoline N-oxide (33) was synthesized by the reaction of ethyl alpha-(o-formylphenyl)acrylate (31), derived from 6 and paraformaldehyde,with hydroxylamine. The cycloaddition of 33 to olefins such as dimethyl maleate, methyl acrylate, and styrene was studied.

  DOI：

  10.1021/jo00077a018

文献信息

• [EN] QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS<br/>[FR] COMPOSÉS DE TYPE QUINAZOLINONE CONVENANT COMME ANTAGONISTES DE CRTH2
  申请人：MERCK SHARP & DOHME

  公开号：WO2012051036A1

  公开（公告）日：2012-04-19

  This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.

  该应用程序提供了Formula I的化合物或其药用可接受盐，其中个别变量在此定义，以及制备这些化合物的过程，包括相同的药物组成和它们在治疗与CRTH2受体相关的疾病状态中的用途。
• Neutral-Eosin Y-Catalyzed Regioselective Hydroacylation of Aryl Alkenes under Visible-Light Irradiation
  作者：Xinxin Tang、Jie Wu、Haiwang Liu、Fei Xue、Mu Wang

  DOI：10.1055/a-1319-6237

  日期：2021.3

  The hydroacylation of styrene derivatives were achieved by employing neutral eosin Y as a direct hydrogen atom transfer (HAT) catalyst under visible-light irradiation. Exclusive anti-Markovnikov selectivity could be obtained. Aldehydes and styrenes with various substituents were tolerated (>20 examples) to achieve products with moderate to high yields. The key acyl radical intermediate was generated

  通过在可见光照射下使用中性曙红 Y 作为直接氢原子转移 (HAT) 催化剂来实现苯乙烯衍生物的加氢酰化。可以获得独特的抗马尔科夫尼科夫选择性。可以容忍具有各种取代基的醛和苯乙烯（> 20 个例子）以实现中等至高产率的产品。关键的酰基自由基中间体由光激发的曙红 Y 诱导的直接 HAT 过程产生。随后加入苯乙烯和反向 HAT 过程产生酮产物。
• FERROPORTIN INHIBITORS AND METHODS OF USE
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US20200190045A1

  公开（公告）日：2020-06-18

  The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.

  本文描述的主题是关于Formula I的Ferroportin抑制剂化合物及其制药盐，制备这些化合物的方法，包含这些化合物的制药组合物以及为预防和/或治疗由于缺乏hepcidin或铁代谢紊乱引起的疾病而给予这些化合物的方法，尤其是铁过载状态，如地中海贫血、镰状细胞病和血色沉着症。
• Michael Additions Involving Amino Acid Esters with Alkenyl N-Heterocycles
  作者：Sean H. Kennedy、Douglas A. Klumpp

  DOI：10.1021/acs.joc.7b01724

  日期：2017.10.6

  variety of amino acid esters and 2- or 4-vinylpyridine. Similar reactions were accomplished with an alkenyl-substituted pyrimidine, pyrazine, thiazole, quinoxaline, benzoxazole, and quinolone. In reactions at a prochiral center, modest diastereoselectivities were observed with the formation of the new stereogenic carbon. NMR experiments indicate that the addition reaction is reversible under acidic conditions

  用多种氨基酸酯和2-或4-乙烯基吡啶可实现迈克尔加成。用烯基取代的嘧啶，吡嗪，噻唑，喹喔啉，苯并恶唑和喹诺酮可以完成类似的反应。在前手性中心的反应中，观察到适度的非对映选择性，并形成了新的立体异构碳。NMR实验表明加成反应在酸性条件下是可逆的。
• USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME
  申请人：Nihon Medi-Physics Co., Ltd.

  公开号：EP2218463A1

  公开（公告）日：2010-08-18

  The invention provides a reagent for detecting amyloid in a biological tissue which can be detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid and is suppressed in toxicity such as mutagenicity. The reagent for detecting amyloid deposited in a biological tissue comprises a compound represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a halogen substituent; R2 is a halogen substituent; and m is an integer or 0 to 2, provided that at least one of R1 and R2 is a radioactive halogen substituent, at least one of A1, A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 and A4.

  该发明提供了一种用于检测生物组织中淀粉样蛋白的试剂，可以利用一种与淀粉样蛋白亲和力强且在毒性方面受到抑制（如致突变性）的化合物，在体外和体内高灵敏度地检测淀粉样蛋白。用于检测生物组织中沉积的淀粉样蛋白的试剂包括下式（1）所表示的化合物或其盐：其中A1、A2、A3和A4独立地代表碳或氮；R1是卤素取代基；R2是卤素取代基；m是整数或0到2，但至少R1和R2中的一个是放射性卤素取代基，A1、A2、A3和A4中至少一个代表碳，且R1与A1、A2、A3和A4所代表的碳结合。